- Home
- MAX vs NAMS Comparison
MAX vs NAMS Comparison
Compare MAX & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MAX | NAMS |
|---|---|---|
| Founded | 2014 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 551.1M | 3.1B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | MAX | NAMS |
|---|---|---|
| Price | $13.00 | $37.03 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 10 |
| Target Price | $17.00 | ★ $45.80 |
| AVG Volume (30 Days) | 486.7K | ★ 1.1M |
| Earning Date | 10-29-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,123,093,000.00 | $35,243,000.00 |
| Revenue This Year | $30.80 | N/A |
| Revenue Next Year | $9.28 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 64.86 | 4.91 |
| 52 Week Low | $7.33 | $14.06 |
| 52 Week High | $13.92 | $42.00 |
Technical Indicators
Market Signals| Indicator | MAX | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 54.64 | 50.68 |
| Support Level | $12.78 | $34.59 |
| Resistance Level | $13.87 | $36.60 |
| Average True Range (ATR) | 0.57 | 1.75 |
| MACD | 0.01 | -0.39 |
| Stochastic Oscillator | 63.35 | 35.29 |
Price Performance
Historical ComparisonAbout MAX MediaAlpha Inc.
MediaAlpha Inc provides a platform that facilitates insurance carriers and distributors target and acquire customers. The company's technology platform brings insurance carriers and consumers together through a real-time, transparent, and results-driven ecosystem. It acts as a customer acquisition channel in the areas of property & casualty insurance, health insurance, and life insurance. It operates in the United States and generates revenue by earning a fee for each consumer referral sold on its platform.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.